2. Academic Validation
  3. Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability

Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability

  • Bioorg Med Chem. 2022 May 15;62:116722. doi: 10.1016/j.bmc.2022.116722.
K Raja Reddy 1,  Maxim Totrov 2,  Olga Lomovskaya 1,  David C Griffith 1,  Ziad Tarazi 1,  Matthew C Clifton 3,  Scott J Hecker 4
Affiliations

Affiliations

  • 1 Qpex Biopharma, Inc, 6275 Nancy Ridge Dr., Suite 100, San Diego, CA 92121, United States.
  • 2 Molsoft L.L.C, 11199 Sorrento Valley Road, San Diego, CA 92121, United States.
  • 3 Beryllium Discovery, 3 Preston Court, Bedford, MA 01730, United States.
  • 4 Qpex Biopharma, Inc, 6275 Nancy Ridge Dr., Suite 100, San Diego, CA 92121, United States. Electronic address: shecker@qpexbio.com.
PMID: 35358864 DOI: 10.1016/j.bmc.2022.116722
Abstract

Early efforts to broaden the spectrum and potency of cyclic boronic acid β-lactamase inhibitor vaborbactam included a series of 7-membered ring boronates. Exploration of stereoisomers and incorporation of heteroatoms allowed identification of the all-carbon cyclic boronate with substituents trans as the preferred core structure, showing inhibition of Class A and C Enzymes. Crystal structures of one analog bound to important β-lactamase Enzymes were obtained. When isolated under acidic conditions, these compounds spontaneously formed a neutral cyclic anhydride (intramolecular prodrug) which was shown to have much-improved oral bioavailability (52-69%) compared to the ring-opened carboxylate salt (9%).

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z